Attitudes toward genomic medicine among US reproductive-age adults and parents enrolled in genomic screening research
While parents enrolled in the BabySeq genomic screening trial initially held more optimistic and less pessimistic attitudes toward genomic medicine than the general US reproductive-age population, their attitudes became more moderate over time regardless of trial arm or genomic results, suggesting that participation alone does not significantly shift public sentiment.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Imagine a world where a simple blood test taken from a newborn could reveal a hidden risk for hundreds of rare genetic diseases long before symptoms ever appear. This is the promise of genomic screening, a medical approach that reads the body's complete genetic instruction book to spot potential health threats early. While this technology offers the chance for timely treatment and peace of mind, its success depends entirely on whether families are willing to participate. For a public health program to work, it needs the trust and interest of the general population. Yet, a critical question has lingered: do the parents who volunteer for research studies represent the views of all parents, or are they a special group with unusually high hopes for this new science? Understanding the gap between those who sign up for trials and the broader public is essential before such screening can become a standard part of healthcare.
Researchers set out to answer this question by comparing the attitudes of two distinct groups: a large, representative sample of American adults of childbearing age, and the parents who had just enrolled their infants in the BabySeq Project, a major clinical trial testing genomic screening. To measure feelings about the future of genetic medicine, the team used a survey tool called the Genomic Orientation scale. This instrument asks people to rate how likely they believe genetic medicine is to bring benefits, such as lowering costs or improving health, versus causing problems, like widening health gaps or reducing personal control. The survey captures two main feelings: optimism, or the belief that the technology will do more good than harm, and pessimism, or the fear that it will create more trouble than it solves.
When the researchers looked at the general population, they found a mix of cautious hope and concern. The average adult in the study held a modestly optimistic view, scoring slightly above neutral on the optimism scale, but also carried a slight degree of pessimism. Interestingly, the survey revealed that current parents were both more hopeful and more worried about genetic medicine than people without children. Those who were planning to have a child in the near future were even more optimistic than those who were not. However, when the researchers turned their attention to the parents who had actually signed up for the BabySeq trial, they found a striking difference. These parents were significantly more optimistic and significantly less pessimistic than the average American adult. At the start of the study, they viewed the potential of genetic medicine with a much brighter outlook, suggesting that families who choose to participate in such research may be more enthusiastic about the technology than the public at large.
The study did not stop at a single snapshot in time. The researchers followed the BabySeq parents over six months, asking them to complete the same survey again after they had received their results. This allowed the team to see if the experience of going through the screening process changed how these parents felt. Over the course of the trial, the parents' views shifted in a specific direction: they became less optimistic and less pessimistic. Their initial high hopes tempered, and their initial fears also subsided. This change happened regardless of whether the family was in the group that received the full genomic sequencing or the control group that received only a standard family history report. It also did not matter if the test found a genetic risk for a disease or if no issues were found. The experience of participating in the study itself seemed to be the catalyst, perhaps helping parents realize that while genetic medicine is powerful, it is not a magic solution for every health problem, and its impact on daily life might be more limited than they initially imagined.
The researchers also examined whether factors like a parent's education level influenced these changing attitudes. They discovered that parents with a high school diploma or less education ended up with lower optimism scores six months after the results were shared, compared to those with more education. This suggests that understanding the nuances of genetic testing might be linked to educational background, or that different groups process the information in distinct ways. However, the study found no evidence that the specific results of the genetic test—whether a family learned their child was at risk or not—altered their overall feelings about the value of genomic medicine. The shift in attitude was a general trend across the group, not a reaction to specific news.
These findings offer a clear warning for those planning to roll out genomic screening as a standard public health program. The parents who volunteer for research studies are not a perfect mirror of the general population; they start with higher expectations and fewer fears. If policymakers assume that the enthusiasm of trial participants reflects the feelings of all parents, they may overestimate how quickly the public will embrace a nationwide screening program. The study suggests that as people learn more about the realities of genetic medicine, their views tend to become more balanced, moving away from extreme hope or extreme worry. For a successful public health initiative, this means that education and communication must be tailored to the general public, acknowledging that their starting point may be more cautious than that of the research volunteers. The path forward requires understanding that while the technology holds great promise, the public's trust will depend on transparent, realistic conversations about what genetic screening can and cannot do.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.